A Fallen Akorn Is Too Expensive for Fresenius

German medical-equipment maker Fresenius SE on Sunday announced it was terminating its $4.3 billion merger agreement with generic drugmaker Akorn Inc. Fresenius said in February it was looking into possible breaches of FDA drug data standards by Akorn, and the results of that probe led it to Sunday's decision. If Fresenius found something in its investigation bad enough to justify breaking off the deal, then it's certainly making the right move. It was a strategic fit for Fresenius and looked relatively cheap after a sales slowdown had hit Akorn's share price.